Dr. Yi-Jia Chen · Synthesis of Acevedo-Fontanez 2026 JAAD review, Tempark 2014 Am J Clin Dermatol, Schwarz 2008 / Veien 1991 / Ollech 2020 JAAD evidence
一句話結論：Perioral dermatitis is a recurring inflammatory skin disease around the mouth, nose, and eyes, with small red papules and pustules; 嘴唇紅色邊緣那一圈會明顯「跳過」不發炎 is the key recognition clue. The most common trigger is topical, inhaled, or oral corticosteroid use. Management hinges on "stopping the trigger + gentle skincare ± topical / oral medication for 4–8 weeks" while avoiding abrupt corticosteroid withdrawal (rebound).
提醒：This article is for general education only and does not replace in-person consultation. Individual drug selection, dose, and duration must be assessed by a dermatologist based on your specific situation.
診間情境：那一片嘴角紅疹
「醫師，我嘴角這幾顆紅疹，我以為是痘痘，買了痘痘藥膏擦兩個禮拜，反而愈來愈嚴重。」
「我擦了家裡剩下的類固醇藥膏，剛開始有變好，可是停藥就又冒出來，現在愈擦愈紅。」
「我家小朋友嘴巴周圍一直紅紅的，是濕疹嗎？皮膚科會給什麼藥？」
這些症狀，很可能是口周皮膚炎（perioral dermatitis；醫學上更精確的稱呼是 periorificial dermatitis, POD）。它常被誤認為痘痘、玫瑰斑或濕疹，但治療方向完全不同——錯把它當濕疹擦類固醇，反而會讓它變嚴重；錯把它當痘痘擦果酸或 A 酸，也可能愈擦愈刺激。
Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008;59(1):34-40. doi:10.1016/j.jaad.2008.03.043. PMID: 18462835. [PubMed]
Veien NK, Munkvad JM, Nielsen AO, Niordson AM, Stahl D, Thormann J. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol. 1991;24(2 Pt 1):258-260. doi:10.1016/0190-9622(91)70038-4. PMID: 2007672. [PubMed]
Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis. J Am Acad Dermatol. 2020;82(6):1409-1414. doi:10.1016/j.jaad.2020.01.064. PMID: 32032693. [PubMed]
Swenson K, Graber E. A single-center pilot study to evaluate the efficacy, safety, and tolerability of sarecycline for treating periorificial dermatitis. J Drugs Dermatol. 2025;24(6):617-620. doi:10.36849/JDD.8590.
Gray NA, Tod B, Rohwer A, Fincham L, Visser WI, McCaul M. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(3):380-390. doi:10.1111/jdv.17817.
Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014;15(2):101-113. doi:10.1007/s40257-014-0067-7. PMID: 24623018. [PubMed]
Hafeez ZH. Perioral dermatitis: an update. Int J Dermatol. 2003;42(7):514-517. doi:10.1046/j.1365-4362.2003.01852.x.
Noguera-Morel L, Gerlero P, Torrelo A, Hernández-Martín Á. Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: a series of 15 cases. J Am Acad Dermatol. 2017;76(3):567-570. doi:10.1016/j.jaad.2016.10.034.
Weber K, Thurmayr R, Meisinger A. A topical erythromycin preparation and oral tetracycline for the treatment of perioral dermatitis: a placebo-controlled trial. J Dermatol Treat. 1993;4(2):57-59. doi:10.3109/09546639309084514.
"Doctor, I have these red bumps around my mouth. I thought they were pimples, used over-the-counter acne cream for two weeks, and now they're worse."
"I tried a leftover steroid cream at home. It looked better at first, but every time I stop it flares up again — and now it's redder than ever."
"My child's mouth area keeps getting red and bumpy. Is this eczema?"
These descriptions often turn out to be periorificial dermatitis (POD), sometimes called perioral dermatitis. It is frequently mistaken for acne, rosacea, or eczema — but the treatment direction is very different. Treating it as eczema with steroids actually makes it worse; treating it as acne with harsh acids or retinoids can be too irritating.
30-second key takeaways
In 30 seconds
The strongest trigger is corticosteroid exposure — topical, inhaled (asthma inhalers), intranasal sprays, oral steroids, and self-applied leftover steroid creams all count.
Typical distribution: small red papules and pustules around the mouth, nose, and eyes, with a characteristic narrow "spared" ring around the vermilion border of the lips.
Not acne: POD has no comedones; comedones point toward acne instead.
Step one is "remove triggers + gentle skincare." Steroids must be tapered, never stopped abruptly (rebound).
Most mild-to-moderate patients clear within 4–8 weeks of topical therapy; severe cases use oral tetracyclines for 4–8 weeks.
POD is not contagious and not systemic, but it can relapse and meaningfully affect quality of life (mean DLQI ≈ 10).
Common patient questions
Q1. How do I tell POD apart from acne?
The single biggest difference is comedones (blackheads / whiteheads). Acne has them, POD does not. POD also clusters tightly around the mouth, nose, and eyes with the vermilion border of the lips spared.
Q2. Can I use my leftover steroid cream?
Please don't self-treat with steroids. They temporarily flatten the rash but typically trigger a worse rebound on withdrawal. If you have already been using a steroid, do not stop abruptly; see a dermatologist who can taper you off gradually.
Q3. What cleanser and moisturizer should I use?
Keep it minimal. A gentle, fragrance-free cleanser; lukewarm water once or twice daily; a light moisturizer. Avoid heavy occlusives (petrolatum, paraffin), strong toners, retinoids, AHAs, and alcohol-containing astringents.
Q4. Is fluoride toothpaste really linked to POD?
Possibly, yes. Fluoride toothpaste is a reported trigger. A practical test is to switch to a non-fluoride toothpaste for 4–6 weeks and watch the perioral area.
Q5. Do I need to stop makeup and sunscreen?
Stop heavy, occlusive products first. Petrolatum-rich balms and heavy occlusive sunscreens are reported triggers. In pediatric POD, mineral (zinc oxide / titanium dioxide) sunscreens have themselves been implicated; a gentle chemical filter can be tried.
Q6. Do I need oral medication? How long until it clears?
For mild-to-moderate disease, topical therapy alone for 4–8 weeks is usually enough. For severe or treatment-resistant disease, oral tetracyclines (typically doxycycline) for 4–8 weeks are added.
Q7. Will it scar or leave dark marks?
Typical POD does not scar, but the granulomatous / lupoid variants can leave small scars. Post-inflammatory hyperpigmentation is common and fades over months; azelaic acid (Skinoren in Taiwan) can speed fading after the active inflammation has settled.
Q8. Can pregnant patients and children be treated?
Yes, with different drug choices. Pregnant patients and children < 8 cannot use tetracyclines but can use topical metronidazole or erythromycin, with oral erythromycin or azithromycin if systemic therapy is needed.
What is periorificial dermatitis?
Periorificial dermatitis (POD) — also called perioral dermatitis — is a relapsing inflammatory facial dermatitis. Although "perioral" is in the name, lesions also commonly occur around the nose (perinasal) and eyes (periorbital), which is why "periorificial" is the more accurate term.
It presents as grouped 1–2 mm erythematous papules and pustules with characteristic vermilion-border sparing; patients describe burning or stinging rather than itch.
Estimated prevalence is 0.1–1%, most commonly in women 20–45 years old; children and older adults are also affected. Mean DLQI scores ~10 indicate moderate-to-severe quality-of-life impact.
Why does it happen? Four pathogenic drivers
POD is multifactorial:
① Epidermal barrier dysfunction
Increased transepidermal water loss (TEWL); the weakened barrier lets irritants, allergens, and microbes penetrate more easily.
② Dysregulated inflammation
Cutaneous T-cell activation; the efficacy of topical calcineurin inhibitors (tacrolimus, pimecrolimus) supports this mechanism.
③ Microbial dysbiosis
Increased Demodex folliculorum, Fusobacterium, and Spirillum species; response to metronidazole and ivermectin supports a microbial component.
④ External triggers (the most actionable category)
Worsening despite over-the-counter creams, especially steroids
Pustules, burning, or stinging appearing
A child with a similar rash and uncertainty about the diagnosis
Cosmetic and emotional impact
Two weeks of simplified routine has not helped
Currently on inhaled or topical steroids and unsure how to wean
How is it diagnosed?
POD is a clinical diagnosis; biopsy and blood tests are usually not needed. The dermatologist will typically ask about all topical products and prescription creams in the past 3 months, inhaled / intranasal / oral steroid use, toothpaste brand and habits (including lip-licking), and — for women — menstrual cycle, oral contraceptive use, and pregnancy plans. Biopsy is reserved for atypical or suspected granulomatous cases.
Three-step treatment ladder
Step 1 (everyone): behavioral changes
Gradually taper any corticosteroid (topical, inhaled, intranasal) under medical supervision — do not stop abruptly
Stop immediately (no taper): heavy occlusive balms, suspect cosmetics, fluoride toothpaste (trial 4–6 weeks)
Switch to a gentle cleanser + light moisturizer for barrier recovery
Be aware that mineral sunscreens can themselves trigger pediatric POD
Step 2 (mild-to-moderate): topical therapy for 4–8 weeks
"Off-label for POD" = the drug's licensed indication is not POD; use is common and clinically reasonable but reimbursement may not apply. Actual NHI coverage follows current Taiwan NHI rules at the time of prescribing.
Oral therapy: who needs it, how to choose
Oral
Adult dose
Best for
Watch-outs
Doxycycline
50–100 mg 1–2× daily
Adults, non-pregnant, age > 8
Photosensitivity; GI upset; do not lie down within 30 min of dosing
Minocycline
50–100 mg 1–2× daily
When doxycycline unsuitable
Rare severe reactions: drug-induced hepatitis, DRESS, pseudotumor cerebri, pigmentation
Erythromycin
500 mg twice daily
Pregnant / breastfeeding; children < 8
GI upset; drug interactions
Azithromycin
500 mg 3 days / week
Alternative
Case-level evidence
Tetracycline (legacy)
250–500 mg twice daily
Less commonly used
Take 1 h before / 2 h after meals; avoid milk / Ca / Mg / Al
Sarecycline
Weight-based
Emerging narrow-spectrum tetracycline
Not yet available in Taiwan
Tetracycline cautions: Absolute contraindications — children < 8, pregnancy (2nd / 3rd trimester), lactation. Caution — hepatic / renal impairment, autoimmune disease. Common side effects — GI upset, photosensitivity, dizziness, candidiasis; interactions with food and divalent cations.
5 common myths
"It's just acne — more acne medication will fix it."
POD has no comedones; harsh BPO / retinoids / AHAs typically aggravate it.
"Steroid creams worked, so they must be the right drug."
Steroids cause severe rebound on withdrawal — the most common reason POD becomes chronic. Tapering must be supervised.
"It's just bad skin / weak immunity, nothing to do."
POD is not immunodeficiency. Most patients improve substantially once triggers are removed and short-course therapy is started.
"It's contagious — avoid sharing towels and dishes."
POD is not contagious and does not spread by towels, dishes, or kissing.
"The more skincare I layer on, the faster it heals."
The opposite is usually true — simplifying skincare is faster than layering multiple actives, many of which are hidden triggers.
More clinical detail — patients may skip this section
Mechanistic detail
Corticosteroids suppress keratinocyte differentiation, disrupt stratum corneum lipid synthesis, and chronically dilate vessels; on withdrawal, NF-κB signaling is disinhibited → rebound inflammation
Epidermal barrier: elevated TEWL allows easier penetration of irritants, allergens, and microbes — fits clinically with the efficacy of calcineurin inhibitors
Microbial axis: increased Demodex folliculorum, Fusobacterium fusiformis, Spirillum; some studies also implicate Neisseriales, Corynebacterium, Cutibacterium, Staphylococcus
Childhood granulomatous POD: monomorphic dome-shaped flesh- to yellow-brown papules; histology — non-caseating granulomatous infiltrate; originally reported in Afro-Caribbean children, since reported across ethnic groups
Lupoid perioral dermatitis: dense red-brown polymorphic papules around the mouth; perifollicular granulomatous inflammation without caseating necrosis on histology
Emerging therapies (most not yet launched in Taiwan)
Topical JAK inhibitors — ruxolitinib 1.5% cream: case reports in refractory POD; watch for acneiform eruption that can mimic disease progression
Topical PDE-4 inhibitors — roflumilast cream: efficacy in AD, psoriasis, seborrheic dermatitis; POD data limited
Sarecycline: 2025 pilot (n=9), all improved, 56% cleared by 4 weeks
Evidence landscape
The 2022 systematic review by Gray et al. concluded that POD RCT evidence is sparse and of low certainty. The 2026 JAAD review reaches the same conclusion: most decisions rely on small trials, case series, and expert experience.
Summary: what you can do
POD is the kind of condition where self-treatment often makes it worse, but professional treatment usually works well. A reasonable action plan:
Stop "all-purpose" creams and heavy occlusive products; try a non-fluoride toothpaste for 1–2 weeks
Switch to a minimal routine: gentle cleanser + one light moisturizer
If two weeks of simplification doesn't help, or you have pustules and burning, see a dermatologist
If you are using a steroid cream: do not stop abruptly — see a dermatologist who will plan the taper
Bring a list of recent topical products, inhalers, and intranasal sprays to the visit
POD is not dangerous or contagious, but left to drift it can become chronic, leave pigment, and drain confidence. Removing triggers, simplifying skincare, and short-course treatment when needed help most patients stay well.
Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008;59(1):34-40. PMID: 18462835.
Veien NK, Munkvad JM, Nielsen AO, Niordson AM, Stahl D, Thormann J. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol. 1991;24(2 Pt 1):258-260. PMID: 2007672.
Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis. J Am Acad Dermatol. 2020;82(6):1409-1414. PMID: 32032693.
Swenson K, Graber E. A single-center pilot study to evaluate the efficacy, safety, and tolerability of sarecycline for treating periorificial dermatitis. J Drugs Dermatol. 2025;24(6):617-620.
Gray NA, Tod B, Rohwer A, Fincham L, Visser WI, McCaul M. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(3):380-390.
Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014;15(2):101-113. PMID: 24623018.
Hafeez ZH. Perioral dermatitis: an update. Int J Dermatol. 2003;42(7):514-517.
Noguera-Morel L, Gerlero P, Torrelo A, Hernández-Martín Á. Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: a series of 15 cases. J Am Acad Dermatol. 2017;76(3):567-570.
Weber K, Thurmayr R, Meisinger A. A topical erythromycin preparation and oral tetracycline for the treatment of perioral dermatitis: a placebo-controlled trial. J Dermatol Treat. 1993;4(2):57-59.
Source notes on Taiwan NHI status and brand names: Taiwan FDA (TFDA) drug labels, Taiwan NHI "Drug Reimbursement Standards" (current revision), Far Eastern Memorial Hospital e-pharm, hospital pharmacy bulletins, Taiwan Dermatological Association 2022 rosacea consensus. NHI coverage rules change over time; rules in force at the time of prescribing apply.
